^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:Zejula (niraparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Peritoneal Cancer)
    New
    Excerpt:
    ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated:...for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:...a deleterious or suspected deleterious BRCA mutation...
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Neuro Oncol
    Title:

    Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models

    Excerpt:
    Daily niraparib increased median survival and decreased tumor burden in the BRCA-mutant MDA-MB-436 model...Niraparib penetrates intracranial tumor tissues in mouse models of TNBC with impressive single-agent efficacy in BRCA-mutant MDA-MB-436.
    DOI:
    https://doi.org/10.1093/noajnl/vdz005